3 / 48
Page 59
Notes:
conferenceseries
.com
November 13-15, 2017 | Las Vegas, USA
14
th
International Conference and Exhibition on
Materials Science and Engineering
RRJOMS | Volume 5 | Issue 7 | November, 2017
Angiogenesis depression effect; a cure for glioblastoma multiforme through oral administration by
lactoferrin-glycyrrhizin conjugate, as HMGB1 antagonist
Hae Jin Kim
1
, Yong-Kyu Lee
2
, In-Kyu Park
3
and
Dong Yun Lee
1
1
Hanyang University, Republic of Korea
2
Korea National University of Transportation, Republic of Korea
3
Chonnam National University Medical School, Republic of Korea
G
lioblastoma multiforme (GBM) is one of the most common and aggressive brain tumors in humans. Recently, to cure GBM
clinically, antiangiogenic therapywithmedications such as Avastin is tried to slow theGBMgrowth. However, this drug can induce
some side effects like stroke and kidney problem. To improve this problem, we newly developed an orally absorbable glycyrrhizin
(GL) that can bind to HMGB1 and overexpression of HMGB1 induces angiogenesis on the tumor tissue. Also, we conjugated GL with
Lactoferrin (Lf) for oral administration, Lf can be absorbed by receptor (Lf-R) that is expressed on the small intestine, blood-brain
barrier (BBB) and glioma cell. We expected potential of GBM region targeting and anti-angiogenesis via HMGB1 capturing, when
the lactoferrin and glycyrrhizin (Lf-GL) was orally administered. Through this research, we confirmed that conjugation between
the Lf-GL, which had increasing HMGB1 binding affinity. In addition, this material showed effect that is growth inhibition of GBM
spheroid and anti-angiogenesis and vascular regression on the in vitro model. And then, we preferentially confirmed effect of LF-GL
on cancer tissue in the xenograft mouse model and proceeded experiments to confirm anti-angiogenesis and possibility of orally
absorbable in the GBM orthotopic mouse model. consequently, these results demonstrated that the Lf-GL would be a novel drug for
the effective treatment of brain tumor.
Biography
Hae Jin Kim graduated from Sejong University, Department of Bioengineering at the age of 24, and progressed to master’s course in Hanyang University. She is mainly
working on cancer. In particularly, she studies the development of newly drug for the treatment of brain cancer and improving the method of administration. She has identi-
fied that the prognosis of disease is poor because drug delivery to the brain was difficult by blood-brain barrier. To improve this problem, she synthesized novel material for
convenient administration method and targeting effect to the brain.
rlagowls42@naver.comHae Jin Kim et al., Res. Rev. J Mat. Sci. 2017, 5:7
DOI: 10.4172/2321-6212-C1-012